First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer

Autor:	Lan Shen, Tan Qiang, Ziming Li, Ding Ding, Yongfeng Yu, Shun Lu
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	crizotinib first‐line chemotherapy non‐small‐cell lung cancer (NSCLC) pemetrexed ROS1 rearrangement Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Cancer Medicine, Vol 9, Iss 10, Pp 3310-3318 (2020)
Druh dokumentu:	article
ISSN:	2045-7634
DOI:	10.1002/cam4.2972
Popis:	Abstract Objectives Food and Drug Administration (FDA) approved crizotinib for advanced ROS1‐rearranged (ROS1+) non‐small‐cell lung cancer (NSCLC) patients due to a single‐arm study PROFILE 1001. However, there is no direct comparison between crizotinib and platinum‐pemetrexed chemotherapy. Materials and methods Clinical data of advanced ROS1+NSCLC patients treated with first‐line crizotinib or platinum‐pemetrexed chemotherapy between August 2010 and December 2017 were analyzed. Results Seventy‐seven patients were eligible, including 30 (39.0%) in the crizotinib group and 47 (61.0%) in the platinum‐pemetrexed chemotherapy group. The median follow‐up was 28.1 months (95% confidence interval [CI]: 19.2‐39.0). The objective response rate (ORR) of crizotinib (86.7%, 95% CI: 73.3‐96.7) was higher than that of platinum‐pemetrexed chemotherapy (44.7%, 95% CI: 29.8‐57.4, P
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/f077e1bb64f34f88b7da2e29a7e169ea Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.